SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL trial results for its GPS leukemia treatment dominate discussion, with topline data expected this month after the trial reached its final analysis milestone. Traders are split between optimism about a potential breakthrough and concern over the binary trial outcome, while sharp price swings have fueled debate about selling pressure and alleged short-term manipulation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian shares are under pressure amid a broader pullback in EV and growth stocks, with traders also focused on the stocks persistent weakness and concerns about cash burn, profitability, and management. Some blame short sellers or trading dynamics, while bulls point to R2 progress and recent operating results as reasons for optimism; those explanations remain debated.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys strong Q3 resultsits first GAAP-profitable quarter, rapid growth in its Vector ad platform, and upbeat outlookhave fueled a sharp rebound and discussion of a possible turnaround. Reported takeover talks with Silver Lake and Saudi Arabias PIF add speculation, with traders debating whether the discussed valuation would undervalue the company or whether a deal will happen at all.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp after-hours drop drew attention as traders linked the move to the FAAs nationwide ground stop after communications problems, while speculation about a cyberattack or AI involvement remained unverified. The discussion also reflected wider pressure on tech and AI stocks tied to uncertainty around Nvidia, with traders divided between seeing the selloff as an overreaction and expecting further weakness.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Reports of an FAA nationwide ground stop tied to air-traffic-control communications problems are drawing attention to AAL, with traders discussing possible departure delays and rerouting. Some characterize the disruption as brief, while speculation about its cause remains unverified.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure and the unresolved CEO succession are driving concern, with traders divided between those calling for his return and those worried about leadership continuity and scrutiny of Nvidias China-related chip sales. Upcoming earnings are another focus, but bullish bets on results and dip-buying compete with fears that uncertainty and further fallout could weigh on the stock.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is selling off after lowering its revenue outlook amid delays activating third-party data-center capacity, prompting analyst concerns about execution and near-term growth; weakness across AI and neocloud stocks, alongside uncertainty around Nvidia, is adding pressure. Traders are split between viewing the delays and higher spending as serious risks and seeing them as temporary setbacks in a business with strong AI demand.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs strong third-quarter results and rapid growth in its Quake AI GPU-cloud business are driving attention as the companys AI-infrastructure pivot gains traction. Bulls point to improving operations and the Anthropic-linked expansion, while skeptics focus on losses, cash needs and financing risks; short-squeeze claims remain speculation.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -8.70% and -24.24%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today reported financial results for the third quarter ended September 30, 2026, and...

Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, announced that its management team will participate in a fireside chat at the upcoming...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Companys Board of Directors...

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common...

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 21, 2026 NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock...

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Arcus Biosciences Inc

Why Did Arcus Biosciences Stock Slump 10% Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The Phase 3 STAR-221 trial compared an anti-TIGIT and anti-PD-1 antibody duo plus chemotherapy to the established nivolumab-based regimen.</li><li>Arcus Biosciences is now concentrating its development resources on its HIF-2a inhibitor, casdatifan.</li><li>The company plans to call for multiple casdatifan data readouts and study initiations throughout 2026.</li></ul>Arcus Biosciences, Inc. (RCUS), announced on Friday that it is stopping its Phase 3 STAR-221 trial after it failed to show meaningful progress.The company will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival.<h2 class="st-heading-2">STAR-221 Study Discontinued</h2>The Phase 3 STAR-221 trial, which compared an anti-TIGIT and anti-PD-1 antibody duo plus chemotherapy to the established nivolumab-based regimen, did not show a survival advantage at the planned interim review.The decision marks a setback for the domvanalimab program, which was being developed alongside zimberelimab for advanced gastric and esophageal cancers.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/RCUS">Arcus Biosciences’ stock</a> traded 10% lower by mid-morning on Friday. On Stocktwits, retail sentiment around the stock changed to ‘extremely bearish’ from ‘bearish’ territory the previous day. Message volume changed to ‘high’ from ‘normal’ levels in the last 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:930/106;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_12_112646_png_edcaeadd11.webp" alt="RCUS’s Sentiment Meter and Message Volume as of 11:15 a.m. ET on Dec. 12, 2025 | Source: Stocktwits" width="930" height="106"><figcaption>RCUS’s Sentiment Meter and Message Volume as of 11:15 a.m. ET on Dec. 12, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Refocusing On Casdatifan</h2>With the STAR-221 trial ending, Arcus is concentrating its development resources on its HIF-2a inhibitor, casdatifan, which has shown encouraging single-agent results in clear cell renal cell carcinoma (ccRCC) studies.&nbsp;Early data demonstrated meaningful improvements in key measures such as response rates and progression-free survival in over 120 patients, and plans call for multiple casdatifan data readouts and study initiations throughout 2026.&nbsp;<blockquote>“The results from STAR-221 are not what we had hoped for, and we have important work ahead to meet the needs of patients on our domvanalimab studies and also accelerate the casdatifan and I&amp;I programs.”-Terry Rosen, CEO, Arcus</blockquote>RCUS stock has gained over 51% in 2025 and over 31% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fuzzy-panda-shorts-new-era-energy-and-digital-stock-we-believe-it-is-gray-s-next-flameout/cLICVVRREFy">Fuzzy Panda Shorts New Era Energy &amp; Digital Stock: ‘We Believe It Is Gray’s Next Flameout’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao.

Arcus will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$17.43
Prev Close	$17.77
Open	$17.58
Dividend Yield	0.00%
50-Day Moving Average	$22.87
Beta	1.57
Avg. Volume	2.49M
PE Ratio	-4.88

52-Week High	$31.74
52-Week Low	$17.43
Market Capitalization	$2.56B
EPS (Annual)	-$3.29
Price to Book	6.33
Revenue Per Employee	$410,981.70

Feed

News

Sentiment

Earnings

Fundamentals

Info

RCUS Fundamentals